A blockbuster cancer drug? TYK’s claims go under the microscope
The medicines company released scanty but promising results for an experimental drug just as its shares were joining the Hong Kong Stock Connect scheme Key Takeaways: The drug being developed…
Increasing losses prompt Zephyrm Bioscience to seek funds through IPO
This biotech company, which focuses on the R&D of stem cell drugs, has filed for listing on the Hong Kong Stock Exchange, hoping to get a slice from the hot…
RELATED ARTICLES
-
Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Cancer drug maker Biostar shines on Hong Kong market debut
2563.HK
-
AstraZeneca could face limited fallout from Chinese tax probe
AZN.US
- IPO pitch puts BrainAurora’s earnings under the microscope
-
NEWS WRAP: AstraZeneca China president assisting in investigation
AZN.US
